Early multimodal vasopressor strategy in septic shock: results of the TRICYCLE randomized controlled trial
Authors' conclusion
Early multimodal vasopressor therapy with Ang II, vasopressin and norepinephrine in patients with septic shock demonstrated promising physiological effects.
Study context
- Population
- Patients with septic shock receiving ≥ 0.15 µg/kg/min of norepinephrine base
- Participants
- 79 patients
- Comparison
- Intervention vs Control
- Interventionn = 38
- Controln = 41reference
- Primary endpoint
- Change in plasma renin concentrations
Methodological detailsphase II
- Phase II
Primary result
As reported in the abstract
Decline in plasma renin concentrations · first 72 h
P = 0.015
Further findings
Decline in lactate concentrations · first 72 h · faster decline in the intervention group
P = 0.006
Reduction in SOFA score · 72 h
P = 0.018
| Outcome | Intervention | Controlper hour | P value |
|---|---|---|---|
| Change in NEE dose (non-prespecified analysis) · 72 hSimilar rate · non-prespecified analysis | - 5.41% per hour | −5.19% | P = 0.47 |
| Change in NEE dose (non-prespecified analysis) · first 24 hSignificantly faster decrease in the intervention group · non-prespecified analysis | - 6.87% per hour | −3.03% | P < 0.0004 |
Safety
Tachyarrhythmias
P < 0.01
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Early multimodal vasopressor strategy in septic shock: results of the TRICYCLE randomized controlled trial. Crit Care. Published 7 September 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →